Jing-Yi is Director of Therapeutic Development of Elixiron Immunotherapeutics. She provides scientific and technical leadership in the preclinical development of therapeutic antibodies for advancing drug candidates into clinical trials. Previously, Jing-Yi served as Senior Manager at Eusol Biotech Co., Ltd., where she was responsible for the design and execution of translational studies to support drug repositioning for Eusol’s clinical asset. Prior to joining Eusol, she was a Research Fellow at Development Center for Biotechnology (DCB), Taiwan. There, she led a R&D project team focused on the development of monoclonal and bi-specific antibodies for cancer immunotherapy. Prior to DCB, she served as a Scientist at BioLegend, Inc. where she participated in the development and manufacturing of several neutralizing antibodies and recombinant proteins. Jing-Yi received her Ph.D. in Molecule Medicine from National Taiwan University and completed postdoctoral training at Gladstone Institute of Virology and Immunology of University of California, San Francisco.